Trial Profile
A Randomised, double-blind, phase II study to evaluate the safety and efficacy of Anti-TGF-beta-1-monoclonal-antibody in patients with Diabetic Nephropathy
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2017
Price :
$35
*
At a glance
- Drugs Anti-TGF-beta-1 monoclonal antibody (Primary)
- Indications Diabetes mellitus
- Focus Therapeutic Use
- 15 Jun 2017 New trial record